Pharma giant, GlaxoSmithkline Consumer Healthcare Ltd has declared that it has bagged final nod from USFDA for Naratriptan Hydrochloride tabs.

The company got nod to sell the tablets in the potencies of 2.5mg base and 1mg base.

Naratriptan hydrochloride pills are prescribed by the physician to put control over migraine attacks in grownups with or without aura.

The parliamentary standing group on health has asked the administration to be cautious about the selling out of major Indian pharmas to multinational corporations, whose growing hold on the drug market it said will make vital medications pricier.

Suven Life Sciences Limited, on Monday, has announced that it has got US patent for two new chemical entities (NCEs) for the treatment of neurological diseases.

In a statement to the BSE, the Hyderabad-based biopharmaceutical company said that U. S. patent office has approved two molecules in the central nervous system
(CNS) arena developed by the company for the treatment of cognitive disorders and these patents are applicable till 2022 and 2024.

Indian pharmaceutical company Aurobindo Pharma Ltd will purchase Hyderabad-based Trident Life Sciences Ltd for about Rs 1.34 billion ($27.85 million).

In a statement to the Bombay Stock Exchange (BSE), Aurobindo Pharma official said, “The board has approved the acquisition of 100 per cent stake of TLSL subject to suitable agreements between the parties for the same and conditions customary to the closing of the transaction.”

Ranbaxy Laboratories, India’s largest pharmaceutical company, announced that the company has received the final approval from the US Food and Drug Administration (USFDA) to make and market Sumatriptan Succinate tablets in the country.

Sumatriptan Succinate tablets are used in treating migraine attacks.

While Ranbaxy got approval for 25 and 50 mg tablets of the drug, Aurobindo got the approval for 100 mg variants apart from 25 and 50 mg.

Pharmaceutical major Strides Acrolab has announced that it has received regulatory sanction for two of its drugs used in the treatment of potentially life-threatening infections.

According to sources, the conglomerate has got approval from US Food and Drug Administration for Sterile Vancomycin in two different capacities.

The products are licensed to Akron-Strides LLC, which is a joint venture between Akron Inc and Strides Arcolab.

Wockhardt, a leading pharmaceutical and biotechnology major, announced that its Chicago-based arm Morton Grove Pharmaceuticals has got sanction from US Food and Drug Administration (USFDA) for selling an oral suspension of a combination of Amoxycillin and Clavulanate Potassium.

According to the sources, the said drug is indicated for the treatment of several common infections, especially in children. The product is marketed in the US by Glaxo SmithKline under the brand name Augmentin 250.

Orchid Chemicals & Pharmaceuticals, a leading Chennai-based pharma major, has revealed that it has got its abbreviated new drug application sanctioned form US Food and Drug Administration to sell anti-epilepsy drug Divalproex sodium tablets in the US.

The company has been allowed to market the drug in the strengths of 125 mg, 250 mg and 500 mg.

Cipla, a leading drug manufacturer, has announced that it has got final sanction from the US Food and Drug Administration (USFDA) to market Pamidronate disodium injection.

The approval has been granted for 30 mg/vial, 60 mg/vial and 90 mg/ vial .

According to the sources, Pamidronate disodium is indicated for the treatment of Paget`s disease of bone and high blood calcium levels. The drug also used in the treatment of osteoporosis, to reduce bone pain associated with certain illnesses and to treat bone loss due to breast cancer.

Eli Lilly & Co., a global pharmaceutical company and one of the world's largest corporations. has informed that it has withdrawn its new-drug application to the U.S. Food & Drug Administration (USFDA) for Cymbalta.

The pharmaceutical firm plans to resubmit application in the first half of next calendar year with supplementary data from a recently completed study in chronic osteoarthritis pain of the knee.